Condition: Healthy Adult Participants · Diabetic Kidney Disease · Sponsor: Mediar Therapeutics
This is a phase 1 randomized, double-blind, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and Pharmacokinetics (PK) of single and multiple ascending doses of MTX-439 administered in healthy adults and adults with diabetic kidney disease (DKD)
This description comes directly from the study's public registry record.
Jeffrey Bornstein, MD · (617) 936-0960 · jeffrey@mediartx.com
Jordan Jara · 617-936-0960 · jordan.jara@mediartx.com
Always discuss trial participation with your own doctor first.
| Doherty Clinical Trials | Melbourne, Victoria, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07473323